The long-termism that Bloomage Biotech adheres to refers to the front-end production capacity layout, key capacity building, investment in basic research, incubation of new businesses, equity incentives, brand building, etc.
In terms of R&D, Bloomage Biotech will adhere to long-termism in 2021, strengthen basic research and applied basic research, continue to innovate in science and technology with R&D strength, build higher barriers to competition, and widen the moat. During the reporting period, R&D investment reached 284 million yuan, a year-on-year increase of 101.43. The number of R&D personnel was 571, an increase of 194 year-on-year. There were 239 projects under research, an increase of 116 year-on-year. There were 89 authorized invention patents, an increase of 40 year-on-year. The company continued to strengthen its core Scientific and technological capabilities continue to lead the independent innovation of the biotechnology industry. The company has 12 new certifications and registrations for raw materials, 2 new medical device registrations, and 8 new special cosmetics administrative licenses.
It is worth noting that Bloomage Biotechnology will also focus on the field of cutting-edge biotechnology "synthetic biology" in 2021. The "Shandong Provincial Key Laboratory of Synthetic Biology of Bioactive Substances" was recognized by the Shandong Provincial Department of Science and Technology in December 2021. The "Synthetic Biotechnology International Innovation Industry Base" built by combining the company's own advantages has been settled in Beijing Daxing Biomedicine Base and will be put into use soon. The synthetic biology R&D team has been initially established and the technical platform has been established.
If you want to know more about Huaxi Biotechnology, it is recommended to consult Huaxi Biotechnology.